A M Fink - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

A M Fink

Showing results (41-50 of 46) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 46 results.

Leukemia|December 3, 2016

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trialJ Edelmann, E Tausch, D A Landau, et al.

Leukemia|March 24, 2020

Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trialsO Al-Sawaf, S Robrecht, J Bahlo, et al.

Leukemia|May 16, 2012

Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemiaT Elter, R James, R Busch, et al.

Leukemia|June 22, 2013

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximabA M Fink, S Böttcher, M Ritgen, et al.

Leukemia|July 27, 2017

Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study groupO Al-Sawaf, S Robrecht, J Bahlo, et al.

Lancet (London, England)|October 5, 2010

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialM Hallek, K Fischer, G Fingerle-Rowson, et al.

Pageof 5

Search research articles

Showing results (41-50 of 46) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 46 results.

Leukemia|December 3, 2016

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trialJ Edelmann, E Tausch, D A Landau, et al.

Leukemia|March 24, 2020

Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trialsO Al-Sawaf, S Robrecht, J Bahlo, et al.

Leukemia|May 16, 2012

Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemiaT Elter, R James, R Busch, et al.

Leukemia|June 22, 2013

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximabA M Fink, S Böttcher, M Ritgen, et al.

Leukemia|July 27, 2017

Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study groupO Al-Sawaf, S Robrecht, J Bahlo, et al.

Lancet (London, England)|October 5, 2010

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialM Hallek, K Fischer, G Fingerle-Rowson, et al.

Pageof 5